Search
4D Molecular Therapeutics Inc
FDMTAdd to Watchlist
10.180USD
+0.110+1.09%
Close 07-31 16:00（ET）Quotes delayed by 15 min
532.17MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of 4D Molecular Therapeutics Inc is 8.18, ranking 162 out of 385 in the Biotechnology & Medical Research industry. The average price target is 33.00, with a high of 45.00 and a low of 17.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
29.100
Target Price
+185.85%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
4D Molecular Therapeutics Inc
FDMT
12
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is 4D Molecular Therapeutics Inc's expected revenue for the next quarter?
4D Molecular Therapeutics Inc's expected revenue is 3.10M.
What is 4D Molecular Therapeutics Inc's price target?
Analysts forecast that 4D Molecular Therapeutics Inc's price target is USD 33.00, with the highest forecast at USD 45.00 and the lowest forecast at USD 17.00.
How have 4D Molecular Therapeutics IncFDMT's recent earnings per share performed?
The market expectation was USD -1.01, while 4D Molecular Therapeutics IncFDMT's earnings per share (EPS) for the previous quarter was USD 0.30. EPS for the next quarter is expected at USD -1.02.
What is the analyst rating for 4D Molecular Therapeutics Inc?
Based on the ratings of 4D Molecular Therapeutics Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.